ABSTRACT
BACKGROUND: Bone marrow angiogenesis is increased in multiple myeloma (MM) patients,prompting the rationale for using antiangiogenic drugs in the treatment of these patients.OBJECTIVE: To assess angiogenesis in patients with MM at diagnosis and following treatmentwith an antiangiogenic drug.Patients and Methods: Twenty-three patients with newly diagnosed MM were treated withthalidomide-based regimens. Bone marrow evaluation was made before and following treat-ment and included angiogenesis assessment, which was quantified through microvesseldensity (MVD) determination, by means of anti-CD34 immunohistochemical labeling, andclassified either as high MVD or low MVD, according to the mean CD34 count: above or belowthe median of 12.6.RESULTS: The pre-therapy median MVD was 12 (7.518.3) versus 8.7 (5.3518.5) post-therapy,p = 0.2114.CONCLUSIONS: Our study found no reduction in MVD before and following treatment and,accordingly, we could establish no relationship between MVD and response to therapy inthe sample we studied.